UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children

Cochrane database of systematic reviews, 2015-11, Vol.2015 (11), p.CD007949

2015

Volltextzugriff (PDF)

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events

Cochrane database of systematic reviews, 2021-04, Vol.4 (4), p.CD007694

2021

Volltextzugriff (PDF)

Crystallographic Structure, Intermolecular Packing Energetics, Crystal Morphology and Surface Chemistry of Salmeterol Xinafoate (Form I)

Journal of pharmaceutical sciences, 2017-03, Vol.106 (3), p.882-891

2017

Volltextzugriff (PDF)

Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma

Luminescence (Chichester, England), 2018-08, Vol.33 (5), p.913-918

2018

Volltextzugriff (PDF)

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Biopharmaceutics & drug disposition, 2017-10, Vol.38 (7), p.407-419

2017

Volltextzugriff (PDF)

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cochrane database of systematic reviews, 2015-10 (10), p.CD008989-CD008989

2015

Volltextzugriff (PDF)

Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo

British journal of clinical pharmacology, 2016-09, Vol.82 (3), p.673-682

Vauquelin, Georges

2016

Volltextzugriff (PDF)

Salmeterol, a Long‐Acting β2‐Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis

Journal of periodontology (1970), 2017-07, Vol.88 (7), p.681-692

2017

Volltextzugriff (PDF)

Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks

Journal of pharmaceutical sciences, 2017-01, Vol.106 (1), p.313-321

2017

Volltextzugriff (PDF)

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease

Cochrane database of systematic reviews, 2015-01, Vol.1 (1), p.CD010139-CD010139

2015

Volltextzugriff (PDF)

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma

Cochrane database of systematic reviews, 2015-06, Vol.2015 (6), p.CD011438-CD011438

2015

Volltextzugriff (PDF)

Enantioselective disposition of (R)‐salmeterol and (S)‐salmeterol in urine following inhaled dosing and application to doping control

Drug testing and analysis, 2017-08, Vol.9 (8), p.1262-1266

2017

Volltextzugriff (PDF)

Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics

Journal of pharmaceutical sciences, 2019-04, Vol.108 (4), p.1401-1403

2019

Volltextzugriff (PDF)

Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: tlast (Common)

Journal of clinical pharmacology, 2016-07, Vol.56 (7), p.794-800

2016

Volltextzugriff (PDF)

External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting

Value in health, 2017-03, Vol.20 (3), p.397-403

2017

Volltextzugriff (PDF)

Bioassay of salmeterol in children using methacholine challenge with impulse oscillometry

Pediatric pulmonology, 2016-06, Vol.51 (6), p.570-575

2016

Volltextzugriff (PDF)

Optimal step-down approach for pediatric asthma controlled by salmeterol/fluticasone: A randomized, controlled trial (OSCAR study)

Allergology International, 2016-07, Vol.65 (3), p.306-311

2016

Volltextzugriff (PDF)

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study

The European respiratory journal, 2016-10, Vol.48 (4), p.1030-1039

2016

Volltextzugriff (PDF)

Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation

British journal of pharmacology, 2021-11, Vol.178 (22), p.4440-4451

2021

Volltextzugriff (PDF)

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

The European respiratory journal, 2018-01, Vol.51 (1), p.1701688-1701688

2018

Volltextzugriff (PDF)

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

The European respiratory journal, 2011-02, Vol.37 (2), p.273-279

2011

Volltextzugriff (PDF)

Regular formoterol plus inhaled corticosteroid vs. salmeterol plus inhaled corticosteroid for asthma

Clinical and experimental allergy, 2023-05, Vol.53 (5), p.491-494

2023

Volltextzugriff (PDF)

Rational design of salmeterol xinafoate imprinted polymer through computational method: Functional monomer and crosslinker selection

Polymers for advanced technologies, 2022-01, Vol.33 (1), p.221-234

2022

Volltextzugriff (PDF)

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results

The European respiratory journal, 2009-09, Vol.34 (3), p.641-647

2009

Volltextzugriff (PDF)

A systems‐level study reveals host‐targeted repurposable drugs against SARS‐CoV‐2 infection

Molecular systems biology, 2021-08, Vol.17 (8), p.e10239-n/a

2021

Volltextzugriff (PDF)

1 – 25 von 311

Suche als RSS-Feed

Aktive Filter

KollektionWiley-Blackwell Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(304)
Mit Volltextzugriff
(293)

Publikationsform

Artikel
(311)

Sprache

Englisch
(311)
Japanisch
(52)

Erscheinungsjahr

n.n

Thema

Salmeterol Xinafoate
(293)
Albuterol - Analogs & Derivatives
(277)
Humans
(266)
Science & Technology
(234)
Life Sciences & Biomedicine
(231)
Male
(164)
Female
(150)
Biological And Medical Sciences
(145)
Medical Sciences
(144)
Asthma - Drug Therapy
(131)
Respiratory System
(121)
Albuterol - Administration & Dosage
(120)
Administration, Inhalation
(112)
Adult
(107)
Salmeterol
(103)
Albuterol - Therapeutic Use
(102)
Pharmacology. Drug Treatments
(102)
Middle Aged
(97)
Albuterol - Pharmacology
(88)
Double-Blind Method
(87)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children

Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events

Crystallographic Structure, Intermolecular Packing Energetics, Crystal Morphology and Surface Chemistry of Salmeterol Xinafoate (Form I)

Utility of Von Pechman synthesis of coumarin reaction for development of spectrofluorimetric method for quantitation of salmeterol xinafoate in pharmaceutical preparations and human plasma

Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers

Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease

Cell membranes… and how long drugs may exert beneficial pharmacological activity in vivo

Salmeterol, a Long‐Acting β2‐Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis

Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks

Indacaterol, a once-daily beta2-agonist, versus twice-daily beta₂-agonists or placebo for chronic obstructive pulmonary disease

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma

Enantioselective disposition of (R)‐salmeterol and (S)‐salmeterol in urine following inhaled dosing and application to doping control

Human Stimulus Factor Is a Promising Peptide for Delivery of Therapeutics

Evaluation of a Scenario in Which Estimates of Bioequivalence Are Biased and a Proposed Solution: tlast (Common)

External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting

Bioassay of salmeterol in children using methacholine challenge with impulse oscillometry

Optimal step-down approach for pediatric asthma controlled by salmeterol/fluticasone: A randomized, controlled trial (OSCAR study)

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study

Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation

Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

Regular formoterol plus inhaled corticosteroid vs. salmeterol plus inhaled corticosteroid for asthma

Rational design of salmeterol xinafoate imprinted polymer through computational method: Functional monomer and crosslinker selection

Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results

A systems‐level study reveals host‐targeted repurposable drugs against SARS‐CoV‐2 infection

Aktive Filter

Suchergebnisse filtern